乙型重型肝炎抗病毒治疗的经验与证据  

Experience and evidence of antiviral therapy for patients with severe hepatitis B

作　　者：辛绍杰[1] 刘鸿凌[1] 

机构地区：[1]解放军第三○二医院肝衰竭诊疗与研究中心,北京100039

出　　处：《传染病信息》2010年第5期311-314,共4页Infectious Disease Information

基　　金：军队"十一五"计划课题(06D006-3)

摘　　要：乙型重型肝炎病情重,病死率高。肝移植是有效的治疗方法,但费用高、等待时间长,限制其在临床的应用。目前治疗仍以内科综合治疗及人工肝治疗为主,抗病毒治疗日益受到重视。本文对近年来国内外乙型重型肝炎的抗病毒治疗资料进行汇总,分析、总结了抗病毒治疗的理论基础、原则与时机及拉米夫定、恩替卡韦等药物的使用经验。建议对存在HBV复制证据的重型肝炎患者进行抗病毒治疗,同时重视其安全性。Patients with severe hepatitis B have poor disease state with a high mortality. Liver transplantation is effective for such patients, but it is limited by the high expense and longer waiting time. Treatment strategies focus on comprehensive internal therapy and artificial liver support therapy, and antiviral therapy has become more and more important. Based on the newest ma- terials of antiviral therapy for severe hepatitis B at home and abroad, the authors analyze and summarize the rationale, principles and timing of antiviral therapy and the experience in the use of antiviral agents such as lamivudine and entecavir, and suggest that it is necessary to take antiviral therapy when there is the evidence of HBV replication, and much attention should be paid to the safety at the same time.

关 键 词：肝功能衰竭 乙型肝炎病毒 核苷类 治疗学 

分 类 号：R575.3[医药卫生—消化系统] R512.62[医药卫生—内科学]